ENANTA PHARMACEUTICALS INC (ENTA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ENTA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ENTA | Lead Director | 64 | ["Chief Financial Officer and Executive Vice President of Tocagen, Inc.", "Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc.", "Vice President, Finance and Chief Financial Officer of Amylin", "management positions with Intermark, Inc. and Triton Group Ltd.", "Audit Manager with Ernst & Young", "interim CFO of Biocept, Inc.", "considerable audit and financial experience in the biotechnology and healthcare sectors"] | [] | 2025 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AMN | Director; Independent Board Chair | 65 | ["Finance/Audit","Healthcare Industry","C-Suite Leadership","Legal/Risk Management","Other Public Company Board Experience","Extensive board leadership experience","Institutional knowledge of the Company","Experience executing oversight responsibilities","Fosters a productive relationship with the CEO","Committed to long-term shareholder value","Promotes independent oversight"] | ["Talent and Compensation Committee"] | 2026 |
| DXCM | Lead Independent Director; Chair | 64 | ["audit committee financial expert"] | ["Audit Committee"] | 2025 |
Biography sourced from the proxy statement filing.
Mark G. Foletta was elected to our Board of Directors in June 2020. Mr. Foletta had been the Chief Financial Officer and Executive Vice President of Tocagen, Inc., a public biotechnology company, from February 2017 until its merger with Forte Biosciences in June 2020. Mr. Foletta previously served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from March 2006 through Amylin s acquisition by Bristol Myers-Squibb Company in August 2012, and as Vice President, Finance and Chief Financial Officer of Amylin from 2000 to 2006. Previously, Mr. Foletta held a number of management positions with Intermark, Inc. and Triton Group Ltd. from 1986 to 2000 and served as Audit Manager with Ernst & Young. From August 2015 to July 2016, Mr. Foletta served as the interim CFO of Biocept, Inc., a public diagnostics company. Mr Foletta is the Lead Independent Director of DexCom, Inc., a public medical device company, and the chairman of the board of directors of AMN Healthcare Services, Inc., a public healthcare services company. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara. We believe that Mr. Foletta s considerable audit and financial experience in the biotechnology and healthcare sectors qualifies him to serve on our Board of Directors.